Enterprise Value to EBITDA Multiple ratio Analysis of Achilles Therapeutics PLC ADR - Deep Dive
Birds's Eye
Fundamentals
Fundamentals
Technicals
MovingAverage
Candlestick
PivotPointLatest FY EV to EBITDA
Period Ending - Dec-23
Excellent EV to EBITDA
1.29
Period Ending - Dec-22
Excellent EV to EBITDA
1.98
Growth
-34.70 %
Trailing Twelve Months EV to EBITDA
Period Ending - Dec-23
Excellent EV to EBITDA
1.21
EV to EBITDA Analysis of Achilles Therapeutics PLC ADR
| Enterprise Value to EBITDA 1.29 of Achilles Therapeutics PLC ADR indicate that a company is more attractive or undervalued in the market. |
| EV to EBITDA Ratio of ACHL drastically fell by -34.70 % this year. |
| EV to EBITDA Ratio with value of 6.98 was highest in Year Dec-19 in last Five Years. |
| EV to EBITDA Ratio of ACHL trending down for at least three Years. |
| Latest EV to EBITDA Ratio with value of 1.29 is lower than Average EV to EBITDA of 3.87 in last five years. |
Other EV to EBITDA Related Info of ACHL that may interest you.
Achilles Therapeutics PLC ADR Overview
| Code | Price | Previous Price | Price Change | Sector |
|---|---|---|---|---|
| ACHL | 0.92 | 0.9397 | 2.10 % | Biotechnology |
Defination of Enterprise Value to EBITDA Multiple
Enterprise Value-to-EBITDA Ratio is used to compare a company's Enterprise Value to its EBITDA (Earnings before Interest, Taxes, Depreciation, and Amortization). It is useful to determine the value of a company, whether it is undervalued or overvalued. more ..
EV to EBITDA Related Ratios
| EBITDAMargin | EVToRevenue | PriceToEarningRatio |
Tsr Value Index
| Poor Value Stock | |
FY - Historical Enterprise Value to EBITDA Multiple of Achilles Therapeutics PLC ADR
| Period | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 |
|---|---|---|---|---|---|---|
| EV to EBITDA | 1.29 | 1.98 | 4.24 | 4.85 | 6.98 | 0 |
| Change | -34.70 % | -53.42 % | -12.61 % | -30.49 % |
FY Chart of Enterprise Value to EBITDA Multiple of Achilles Therapeutics PLC ADR
Note : All Data Generated at the End of Trading Hours (EOD Data)